Metastatic TNBC: ipatasertib extends PFS benefit of front-line paclitaxel

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • In patients with metastatic triple-negative breast cancer (TNBC), median PFS is prolonged who received the novel drug ipatasertib plus paclitaxel (Abraxane) vs placebo plus paclitaxel.

Why this matters

 

 

  • Because metastatic TNBC has a poor prognosis, this phase 2 trial offers hope for a new class of drug, AKT inhibitors, and warrants further study in a phase 3 trial.

Study design

 

 

  • In this randomized, placebo-controlled, double-blind, phase 2 trial, 124 patients were randomly assigned to paclitaxel (80 mg/m2) plus ipatasertib (400 mg) or paclitaxel plus placebo every 28 d until disease progression or unacceptable toxicity.
  • Funding: F. Hoffmann-LaRoche.

Key results

 

 

  • The ipatasertib group had longer median PFS of 6.2 mo vs 4.9 mo with placebo (HR, 0.60; P=.037).
  • 23% of the ipatasertib group had diarrhea as a grade 3 or worse adverse event vs 0% of the placebo group.
  • 28% of the ipastasertib group had serious adverse events vs 15% of the placebo group.

Limitation

 

 

  • Relatively small sample sizes.